Senate Bill 3072
116th Congress(2019-2020)
SAVE Moms and Babies Act of 2019
Introduced
Introduced
Introduced in Senate on Dec 17, 2019
Overview
Text
Introduced
Dec 17, 2019
Latest Action
Dec 17, 2019
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
3072
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Mississippi
Nebraska
Arkansas
Florida
Indiana
Indiana
Louisiana
Mississippi
Missouri
Missouri
Arkansas
Nebraska
North Carolina
North Dakota
North Dakota
Oklahoma
South Carolina
South Carolina
South Dakota
South Dakota
Wyoming
No Senate votes have been held for this bill.
Summary

Support And Value Expectant Moms and Babies Act of 2019 or the SAVE Moms and Babies Act of 2019

This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.

Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.

The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner to also act as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.

The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)

Text (1)
December 17, 2019
Actions (2)
12/17/2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
12/17/2019
Introduced in Senate
Public Record
Created
Dec 18, 2019 5:42:14 AM
Updated
Jun 11, 2021 10:01:27 PM